The unique calcium chelation property of poly(vinyl phosphonic acid-co-acrylic acid) and effects on osteogenesis in vitro

Qi Guang Wang,1,2 Ian Wimpenny,3 Rebecca E. Dey,4 Xia Zhong,4 Peter J. Youle,4 Sandra Downes,3 David C. Watts,5 Peter M. Budd,6,4 Judith A. Hoyland,2,6 Julie E. Gough3

1National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China
2Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, United Kingdom
3School of Materials, The University of Manchester, Manchester, M13 9PL, United Kingdom
4School of Chemistry, University of Manchester, Manchester, M13 9PL, United Kingdom
5Division of Dentistry, School of Medical Sciences and Photon Science Institute, University of Manchester, Manchester, M13 9PL, United Kingdom
6NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

Received 7 June 2017; revised 14 August 2017; accepted 22 August 2017
Published online 26 September 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.a.36223

Abstract: There is a clear clinical need for a bioactive bone graft substitute. Poly(vinyl phosphonic acid-co-acrylic acid) (PVPA-co-AA) has been identified as a promising candidate for bone regeneration but there is little evidence to show its direct osteogenic effect on progenitor or mature cells. In this study mature osteoblast-like cells (SaOS-2) and human bone marrow-derived mesenchymal stem cells (hBM-MSCs) were cultured with PVPA-co-AA polymers with different VPA:AA ratio and at different concentrations in vitro. We are the first to report the direct osteogenic effect of PVPA-co-AA polymer on bone cells and, more importantly, this effect was dependent on VPA:AA ratio and concentration. Under the optimized conditions, PVPA-co-AA polymer not only has an osteoconductive effect, enhancing SaOS-2 cell mineralization, but also has an osteoinductive effect to promote hBM-MSCs’ osteogenic differentiation. Notably, the same PVPA-co-AA polymer at different concentrations could lead to differential osteogenic effects on both SaOS-2 and hBM-MSCs in vitro. This study furthers knowledge of the PVPA-co-AA polymer in osteogenic studies, which is critical when utilizing the PVPA-co-AA polymer for the design of novel bioactive polymeric tissue engineering scaffolds for future clinical applications. © 2017 The Authors Journal of Biomedical Materials Research Part A Published by Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 168–179, 2018.

Key Words: polyvinyl phosphonic acid, acrylic acid, osteoinductivity, osteoconductivity, calcium chelation

How to cite this article: Wang QG, Wimpenny I, Dey RE, Zhong X, Youle PJ, Downes S, Watts DC, Budd PM, Hoyland JA, Gough JE. 2018. The unique calcium chelation property of poly(vinyl phosphonic acid-co-acrylic acid) and effects on osteogenesis in vitro. J Biomed Mater Res Part A 2018:106A:168–179.

INTRODUCTION

Bone is a type of tissue with a self-healing capability. However, bone fractures beyond the critical size: 3 cm for the forearm, 5 cm in the femur and tibia, 6 cm in the humerus; are always associated with impaired healing, resulting in a delayed union or nonunion. With large bone defects, post-traumatic injuries or revision total hip replacement surgeries, surgery requires bone grafts/void fillers to be placed between bones or the bone and prosthesis, to bridge the gap or stabilize and promote bone growth and integration. Consequently, bone grafting is a common surgical procedure, and it has been estimated >2 million grafting procedures are performed worldwide each year. Hence there is a clear clinical need for bioactive bone void filler.

Tissue engineering is a promising strategy to create bioactive bone void filler. It uses biocompatible and biodegradable materials to provide temporary structural support and to stimulate new bone growth. With the recent technology advancements on scaffold biological functionality, researchers have focused on creating a bioactive scaffold that mimics the native bone extracellular matrix with both osteoconductive and osteoinductive properties. This can be achieved through the incorporation of bioactive moieties, such as polymers, growth factors, or proteins, into or onto the scaffold.

Poly vinyl phosphonic acid-co-acrylic acid (PVPA-co-AA) has been identified as a potential candidate to enhance bone growth by incorporating it within a scaffold. It has been hypothesized to mimic the action of bisphosphonates, due to a similar chemical structure and the ability of the
phosphonate group to chelate Ca$^{2+}$ ions, essentially forming a “bone hook,” with the potential to enhance bone mineralization.$^9$ Previous studies utilized PVPA-co-AA as a surface treatment of electrospun tissue engineering scaffolds, demonstrating improved surface wettability, compressive strength, cell viability and bone formation.$^{10–12}$ However, factors such as scaffold topography, porosity, pore size, interconnectivity, and so forth can also contribute to the osteogenic effect of a scaffold,$^{13}$ and thus it is unclear whether the effect in these previous studies was a result of a direct osteogenic effect on cells, or improved wettability of the scaffold surface caused by the addition of the PVPA-co-AA polymer. Furthermore, conflicting results have also been reported in that the PVPA-co-AA treated samples induced little to no mineralization on collagen scaffolds.$^{14}$ Hence, the exact nature by which PVPA-co-AA influences bone regeneration needs to be further investigated to realize its clinical potential and the mode of action of PVPA-co-AA following incorporation into bioactive bone grafts.

PVPA-co-AA is derived from two monomers, vinyl phosphonic acid (VPA) and acrylic acid (AA), and thus has both phosphonic acid and carboxylic acid functional groups. Both of these are capable of chelating calcium (Fig. 1) and have been previously used in bone tissue engineering scaffolds. Poly vinyl phosphonic acid (PVPA) has been utilized with chitosan or polyvinyl alcohol scaffolds to treat rat calvarial defects, and more pronounced tissue growth and bone formation was observed after in vivo implantation.$^{10,13}$ Poly acrylic acid (PAA) has been used within chitosan–silica hydrogels carrying platelet gels for bone defect repair$^{16}$ and nanocomposites of PAA nanogels and biodegradable polyhydroxybutyrate have been employed in bone regeneration and drug delivery.$^{17}$ Therefore, both the VPA and AA units in the PVPA-co-AA polymer may enhance bone regeneration, and the optimized combination/ratio in the PVPA-co-AA copolymer requires further understanding.

The objective of this study was to determine if there is a direct biological effect of PVPA-co-AA on bone cells, including cell viability, metabolic activity, alkaline phosphatase activity, collagen synthesis, and the production of a mineralized matrix in vitro. As both the VPA and AA components in the copolymer have an ability to chelate calcium, hence promoting bone mineralization, we hypothesize that different VPA:AA ratios in the PVPA-co-AA polymer may lead to differential osteogenic effects. In particular, we investigated the osteoinductive and osteoconductive effect of PVPA-co-AA polymers using the human bone marrow derived mesenchymal stem cells (hBM-MSCs) and an osteoblast cell line, SaOS-2 cells.

**MATERIALS AND METHODS**

**Materials**

PVPA-co-AA polymers with different AA and VPA ratios were synthesized in house.$^{18}$ Six PVPA-co-AA polymers with different AA-VPA ratios (mol %) of 0:100 (PAA), 22:78 (P-22), 34:66 (P-34), 56:44 (P-56), 78:22 (P-78), and 100:0 (PVA) (Table I) were used in this study. Prior to cell culture, all PVPA polymers were diluted to 10 mg/mL concentration in PBS and adjusted to pH 7.3, followed by autoclave sterilization.

**Cell culture**

Human bone marrow was removed from the proximal femur during hip-replacement surgery after approval from the North West Research Ethics Committee and with fully informed written consent of patients (male, $n = 3$; average age, 52 years (age range, 48 to 54 years)). hBM-MSCs were isolated and expanded in Minimum Essential Media α (α-MEM) (Sigma-Aldrich, UK) with 20% FCS, as previously described.$^{19}$ After 5 days, nonadherent cells were discarded, and adherent cells were cultured to confluence. hBM-MSCs were subsequently cultured in α-MEM supplemented with 10% FCS, antibiotics (100 U/mL Penicillin, 100 mg/mL streptomycin), 1% Glutamax and 10 μM ascorbic acid (referred to as hBM-MSCs CCM). hBM-MSCs at passage 3 were used for subsequent experiments.

Human osteosarcoma derived osteoblast cells (SaOS-2) were purchased from Sigma (Sigma-Aldrich, UK) and cultured in T75 flasks with Dubecco’s modified Eagles media (DMEM) (Sigma-Aldrich, UK) supplemented with 10% fetal calf serum (FCS), antibiotics (100 U/mL Penicillin, 100 mg/mL streptomycin), 1% Glutax and 10 μM ascorbic acid (referred to as SaOS-2 CCM). They were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO$_2$.

**Cell viability and metabolic activity**

SaOS-2 cells were seeded into 24-well plates, at a density of 40,000 cells per well. After 24 hours a range of PVPA-co-AA copolymers were added to the cell culture media at concentrations ranging from 0 to 200 μg/mL. After 24, 48, and 72 hours, the cell culture medium was harvested and the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) test was used to determine cell viability.$^{20}$

**TABLE I. Six PVPA-co-AA Polymers with Different AA-VPA Ratios (mol %)**

| Sample Code | Monomer Feed Ratio (VPA:AA) | Copolymer Composition (VPA:AA) | Molecular Weight (g mol$^{-1}$) |
|-------------|-----------------------------|-------------------------------|--------------------------------|
| PAA         | 0:100                       | 0:100                         | 362,000                        |
| P-22        | 30:70                       | 22:78                         | 267,000                        |
| P-34        | 40:60                       | 34:66                         | 18,200                         |
| P-56        | 60:40                       | 56:44                         | 19,700                         |
| P-78        | 80:20                       | 78:22                         | 9400                           |
| PVA         | 100:0                       | 100:0                         | 9400                           |
concentrations (0 to 1 mg/mL) were then added to human SaOS-2 cells cultures for 7 days. The media was replenished every 2–3 days, and cell viability and metabolic activity was measured at day 0, 1, 3, and 7.

Cell viability was assessed using the Live/Dead Cell Double Staining Kit (Sigma-Aldrich, Poole). The kit contains calcein-AM and propidium iodide, which stain viable and nonviable cells, respectively. Fluorescence was detected at 490 nm excitation for simultaneous monitoring of viable and dead cells. Two hundred cells were counted in three separate regions of each well (4 replicates). Percentage viability was assessed by dividing the number of viable cells by the total number of counted cells.

For cell metabolic activity, the AlamarBlue® Cell Viability Reagent (Invitrogen, UK) was used. In brief, initial metabolic activity (day 0) was measured using the Alamar Blue assay, before 0–500 μg/mL of the PVPA-co-AA solution was added to the culture media. Phosphate buffered saline (PBS) was used as a control and a number of PVPA-co-AA solutions were tested, with VPA contents ranging from 0 to 100 mol % at the different concentrations from 10 to 1000 μg/mL. Cell metabolic activity was then measured at 24 h and 72 h time points. The resulting fluorescence was read on a plate reader (FLx800, Biotek, UK) with an excitation wavelength of 540 nm and an emission wavelength of 600 nm. The fold change in SaOS-2 cell number was calculated by comparing the cell number at day 1, day 3 and day 7, to day 0 (3 replicates). The statistical difference between each treatment and the PBS control was compared using the one-way ANOVA analysis.

**Calcium chelation test**

The amount of Ca\(^{2+}\) chelated by the PVPA-co-AA polymer was measured using a calcium-ion-selective electrode (calcium ISE) from ThermoFisher Scientific, UK. A range of PVPA-co-AA copolymers (5 mg mL\(^{-1}\)) were dissolved in 0.1 M NaCl solutions in deionized water and neutralized to the required pH 7.3 using 0.1 M NaOH. CaCl\(_2\) (0.1 M) was added to the polymer solutions which were then stirred for 30 min. The calcium ISE was then immersed into the polymer solutions to measure the free Ca\(^{2+}\) concentration. A calibration curve was produced prior to the measurement using a range of CaCl\(_2\) standard solutions (0.0001, 0.001, 0.01, 0.1, and 1 M). The samples were then quantified by means of the calibration curve \((R^2 > 0.999)\). The amount of polymer-bound calcium was calculated from the total amount of Ca\(^{2+}\) added and the amount of free Ca\(^{2+}\) measured.

**PVPA-co-AA treatment in osteogenic media**

hBM-MSCs were seeded in 48-well plates at a density of 20,000 cells per well in 0.5 mL hBM-MSCs CCM until they reached confluence (usually after 72 h). To promote osteogenic differentiation, the media was then replaced with the hBM-MSCs osteogenic media (hBM-MSCs OM), which was α-MEM supplemented with 10% FCS, antibiotics (100 U/mL Penicillin, 100 μg/mL streptomycin), 1% Glutamax, 10 nM dexamethasone, 50 μg/mL L-ascorbic acid and 5 mM inorganic phosphate (Sigma-Aldrich, UK).

SaOS-2 cells were seeded in 24-well plates at a density of 40,000 cells per well in 1 mL SaOS-2 CCM until they reached confluence. After 72 h media was replaced with the SaOS-2 osteogenic media (SaOS-2 OM), which was the DMEM supplemented with 0.5% FCS, antibiotics (100 U/mL Penicillin, 100 μg/mL streptomycin), 10 mM dexamethasone and 50 μg/mL L-ascorbic acid (Sigma-Aldrich, UK). Two days prior to the end of the experiment, 5 mM inorganic phosphate was added to the osteogenic media to promote mineralization.

PVPA-co-AA polymers with various AA-VPA ratios at a range of concentrations (0 to 100 μg/mL) were added into the corresponding osteogenic cultures throughout the entire period, and replenished every 2–3 days with the media change. hBM-MSCs were cultured in hBM-MSCs OM up to 28 days and SaOS-2 cells were cultured in SaOS-2 OM up to 7 days, while various analyses were performed at different time points.

**Alkaline phosphatase assay**

hBM-MSC samples in hBM-MSCs OM were analyzed at day 14 and SaOS-2 cell samples in SaOS-2 OM were analyzed at day 7. The cells were washed with PBS and fixed in 4% paraformaldehyde for 1 min. Cells were then washed once with PBS containing 0.05% Tween and stained with BCIP/NBT assay solution (SigmaFast™ BCIP-NBT; Sigma Aldrich) for 10 min. The plates were washed three times with PBS with 0.05% Tween and air-dried prior to scanning on a flatbed scanner. The percentage area of mineralization per well was quantified using Image J (http://imagej.nih.gov/ij/) and expressed as percentage response to different PVPA-co-AA treatments.

**In vitro mineralization assay**

hBM-MSC samples in hBM-MSCs OM were analyzed at day 21 and SaOS-2 cell samples in SaOS-2 OM were analyzed at day 7. The cells were fixed overnight in 4% paraformaldehyde and stained with 40 mM Alizarin Red S (pH 4.2, Sigma-Aldrich, UK) for 45 min. The plates were washed four times with distilled water and air-dried prior to scanning on a flatbed scanner. The percentage area of mineralization per well was quantified using Image J and expressed as percentage response to different PVPA-co-AA treatments.

**Picrosirius red collagen assay**

hBM-MSCs samples in hBM-MSCs OM were analyzed at day 28 and SaOS-2 cell samples in SaOS-2 OM were analyzed at day 7. The cells were fixed in 100% ethanol overnight at –20°C. The cells were washed once with PBS and incubated in PicroSirius Red staining solution (0.1%) (Sigma-Aldrich, UK) at room temperature for 1 hour. The staining solution was removed, and the samples were washed three times with 0.1% acetic acid to remove the excessive staining residues. The plates were washed by PBS with 0.05% Tween three times and air-dried prior to scanning on a flatbed scanner. The percentage area of mineralization was...
quantified using Image J and expressed as percentage response to different PVPA-co-AA treatments.

**Scanning electron microscopy (SEM)**
The structures of calcium-chelating polymers and the morphology of the cells cultured on Thermanox® coverslips and polymer samples were observed by scanning electron microscopy. Calcium chelating polymers were prepared in a CaCl₂ solution at concentrations in excess of the maximum chelation capacity of each polymer (PAA, P-34 and PVPA). Calcium-polymer complexes were centrifuged (5 min at 5000 rpm). The pellet was re-suspended in 100% ethanol and centrifuged and the process repeated twice with a final wash in dH₂O. Samples were frozen at −80°C and freeze dried for 24 h. Samples were adhered to aluminum stubs with conductive carbon tape and sputter-coated with gold (Edwards, UK) prior to imaging. Calcium-chelated polymers were observed using a Phenom G2 Pro desktop scanning electron microscope (SEM; Eindhoven, Netherlands) with an accelerating voltage of 5 kV. Samples that had been cultured with cells were imaged using a variable pressure SEM (Zeiss EVO60; Carl Zeiss Ltd, UK).

**Quantitative real-time PCR**
hBM-MSCs samples in hBM-MSCs OM were analyzed at days 0, 21 and 28, while SaOS-2 cell samples in SaOS-2 OM were analyzed at days 0, 1 and 5. At each time point, the cells were washed by PBS twice and lysed with 1 mL TRIzol reagent (Life Technologies, UK), then incubated for 5 min with constant agitation. After incubation, the RNA was extracted as previously described, quantified using a Nanodrop and reverse-transcribed to cDNA, using a High Capacity cDNA Reverse Transcription Kit (Life Technologies, UK). Real-time quantitative polymerase chain reaction (PCR) was performed on a StepOnePlus real-time PCR system (Life Technologies, UK), using Lumino-Ct qPCR ReadyMix (Sigma-Aldrich, UK).

Assays were prepared using FAM-BHQ1 assays (all primers and probes from Sigma-Aldrich) for the following genes: alkaline phosphatase (ALPL; NM_000478), forward AGCTTTCCATTTTGTTG, reverse GTAGTTGTGTGAGCACCTA; collagen type I (COL1; NM_000089), forward TCCGGTTGTGTGAGCACCTA, reverse CTGGGCTTTCTTACAG; osteopontin (OP; NM_000582), forward CTGATCCCATCCCTG, reverse CAGCTGACTCGTTTCATA; runt-related transcription factor 2 (RUNX2; NM_001024630), forward CTGGGCTTTCTTACAG, reverse CTGGGCTTTCTTACAG; osteocalcin (OC; NM_199173), forward CCGACTCGTTACTG, reverse GCCATTGATACAGTAC. The gene expressions were normalized to housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH; NM_001256799), Forward CTGCCATCTGACACT; Reverse CGTGTCTACACAG; and represent mean ± SD.

**RESULTS**

**Optimized PVPA-co-AA concentrations for cell culture**
Viable SaOS-2 cells were observed at all test PVPA-co-AA concentrations after 7 days' culture, with the cell viability above 95% in all test samples. However, there were visually fewer cells with the 1000 μg/mL PVPA-co-AA treatment [Fig. 2(A)]. Figure 2(B) shows that compared to PBS control, the cell metabolic activity was not significantly different at PVPA-co-AA polymer concentrations of 10 μg/mL and 100 μg/mL throughout the 7-day culture period. In contrast, at 500 μg/mL concentration, the cell metabolic activity was significantly decreased compare to the P-22, P-56, and PVPA treatment at day 7. At 1000 μg/mL concentration, the cell metabolic activity was significantly decreased with the P-22, P-34, P-56, and PVPA treatment at day 3 and day 7; and P-78 treatment at day 7. In contrast, no significant difference in cell metabolic activity was found with the PAA treatment compare to PBS control. Overall, all PVPA-co-AA treatments at concentrations of 100 μg/mL or lower showed no effect on cell metabolic activity up to 7 days. Hence PVPA-co-AA concentrations were kept below 100 μg/mL in subsequent cell work.

**The unique calcium chelation property of the PVPA-co-AA polymer**
PVPA-co-AA is a polyelectrolyte of intermediate strength. Figure 3(A) illustrates the dissociation of phosphonic and carboxylic acid groups to give a negatively-charged polyelectrolyte in aqueous solution. PVPA-co-AA can chelate calcium ions to form a clear, soluble complex. This occurs when the capacity of the polymer is higher than the calcium concentration added into solution [Fig. 3(B)]. When the capacity of PVPA-co-AA is equal to the calcium concentration, interpolymer complexes are formed, producing a cloudy solution [Fig. 3(C)]. Finally, an overabundance of calcium ions in solution will lead to precipitation of the polymer-calcium complex [Fig. 3(D)].

The calcium chelation capacity of each PVPA-co-AA polymer was assessed [Fig. 4(A)] Calcium chelation increased with VPA content from 22% to 34%, after which there was a decrease with increasing VPA mol %.

**The VPA:AA ratio of PVPA-co-AA polymer affected the amount of mineralization in SaOS-2 cells**
The 7-day *in vitro* mineralization staining patterns with various PVPA-co-AA treatments are shown in Figure 5(A) with quantitation depicted in Figure 5(B). With 5 μg/mL PVPA-co-AA treatment, three polymers; PAA, P-22, and P34 showed significantly higher mineralization than the control while the other polymers showed significantly lower mineralization than the control. With 10 μg/mL PVPA-co-AA treatment, two polymers; P-22, and P34 showed significantly higher mineralization than the control while the other polymers showed significantly lower mineralization than the control. With PVPA-co-AA treatment at 25 μg/mL or above, all treatment samples showed significantly lower or even no mineralization at all, compared to the control. Similar to the calcium chelation capacity, the cell mineralization was increased with VPA content from 22% to 34%, after which there was a decrease with increasing VPA% [Fig. 4(B)].
The VPA:AA ratio of PVPA-co-AA polymer affected the cell mineralization pattern

The solutions themselves had very different appearances when observed visually. For example, PAA produced a rather turbid solution, P-34 was less cloudy with some precipitate and PVPA demonstrated a clear supernatant with a stable precipitate at the base of the centrifuge tube. This was thought to indicate that interpolymer-calcium complexes may possess different properties, in terms of propagation of particle formation and potential for ionic exchange. The calcium-interpolymer complexes of PAA, P-34, and PVPA-co-AA polymers were freeze dried and investigated by SEM to observe the difference in the physical morphology. Distinct differences in the complexes could be observed by SEM (Fig. 6). PAA appeared to be a flaky, porous polymer film. It was considered that the pores were created as a result of...
sublimation of the ice crystals during the process of freeze drying. However, P-34 appeared to have formed distinct large particles. It appeared that smaller particles may have acted as nucleation sites and the particles continued to agglomerate to form relatively large, dense clusters, with an appearance similar to bone nodules [Fig. 6(A)]. Finally, the PVPA homo-polymer also demonstrated the formation of particulates, but they appeared smaller and better dispersed (limited agglomeration). The size and shape of calcium phosphate particles and their chemistry is known to affect the cell-bioceramic interaction, causing changes in protein expression and affecting further mineralization of the surface.

The chelation capacity of the pure constituent polymers and the ratio of these constituents in the copolymers clearly affected the morphology of the mineralized component that can interact with the cells. The extent and morphology of the mineralized matrix was observed in association with SaOS-2 cells after 7 days' culture in osteogenic media. All the polymer-associated samples demonstrated regions of mineralized matrix production. However, relative to the control (thermanox coverslip), the matrix was much more densely packed [Fig. 6(B)]. PAA, P-22, and P-34 presented similar levels of confluence and matrix distribution across the surface of the coverslips. However, as the molar ratio of VPA increased from 34 mol %, the deposition of matrix was less homogenously distributed, with a tendency to form clusters of mineralized matrix, leaving large areas of the underlying coverslip exposed. This may be as a result of cells adhering to the larger, distinct polymer-calcium complexes, previously observed in the polymer-calcium complexes in solution. These observations were consistent with the distribution of positive (red) alizarin red staining for the presence of calcium [Fig. 6(C)].
Since P-34 showed the best overall results in calcium chelation capacity and amount of mineralization in culture experiments, indicating the optimized VPA:AA ratio among all tested polymers, it was selected for further study.

Osteogenic effect of P-34 on hBM-MSCs was concentration dependent

hBM-MSCs cells were cultured in osteogenic media with different concentrations of PVPA (P-34) for 14 days and alkaline phosphatase activity and in vitro mineralization assessed at day 7; and collagen synthesis assessed at day 14 [Fig. 7(A)]. The results show that at 10 μg/mL and 25 μg/mL concentrations, P-34 treatment significantly increased alkaline phosphatase activity at day 7. At 5 μg/mL and 10 μg/mL concentrations, P-34 treatment significantly increased in vitro mineralization at day 7 and the collagen synthesis at day 14.

P-34 significantly increased osteogenic gene expression in hBM-MSCs

Human hBM-MSCs treated with P-34 showed increased expression of all genes compared to the PBS control [Fig. 8(A)]. The osteogenic marker gene ALPL was significantly higher in the treatment group at both day 21 and day 28; COL1 was also significantly increased at day 21 in the P-34 treated samples. RUNX2 and OP both showed a significant increase at day 28 in samples treated with P-34. The mature osteoblast marker gene OC was not detected in any day 21 samples and only detected in less than half of the day 28 samples after 35/40 PCR cycles and thus results were not analyzed.

P-34 increased ALPL gene expression in SaOS-2 cells at day 1 but no other gene expression was significantly increased compared to PBS control. Osteogenic gene expression in SaOS-2 cells was not increased with P-34 treatment [Fig. 8(B)] throughout the 7-day culture period.

DISCUSSION

In this study, a range of PVPA-co-AA polymers with the VPA:AA ratio from 0 to 100 have been tested; no cytotoxicity was seen at concentrations of 100 μg/mL or below. Among the tested PVPA-co-AA polymers with different VPA:AA ratios, only the co-polymer with VPA:AA ratio no >34:66 mol %, at a concentration of no >25 μg/mL enhanced the BM-MSCs and SaOS-2 cells mineralization in vitro.

The effect of copolymer composition on the calcium chelation capacity has been investigated and related to the ability of the polymers to affect cell matrix mineralization in vitro. We have proposed a mechanism for the calcium chelation of PVPA-co-AA copolymers. In aqueous solution, the carboxylic and phosphonic acid groups of PVPA-co-AA will dissociate to form a negatively-charged polyelectrolyte. These acid groups are capable of binding to divalent calcium ions. When the concentration of calcium is high, relative to the polymer concentration, inter-polymer complexes may be formed. This occurs as a result of calcium binding to acid groups from separate polymer chains, forming electrostatic "crosslinks." At very high calcium concentrations, an insoluble polymer-calcium complex is formed which precipitates out of solution.

FIGURE 5. Effect of different PVPA-co-AA polymer treatments at different concentrations on SaOS-2 cells mineralization. (A) Representative photos showing the patterns of alizarin red S staining of the in vitro mineralization matrix subject to PVPA-co-AA polymer treatments at different concentrations. (B) Shows the quantified percentage of SaOS-2 cells mineralization subject to PVPA-co-AA polymer treatments at different concentrations. The graph shows means ± SD of data. ± indicates the significant increase or decrease (at least $p < 0.05$) in the mineralization percentage vs. the control samples.
There was a notable similarity of the calcium chelation capacity of each PVPA-co-AA polymer and its effect on SaOS-2 cells mineralization in vitro: with the higher calcium chelation capacity, the greater effect on SaOS-2 cells mineralization in vitro was achieved. It also shows the possible correlation of the calcium chelation capacity and the mineralization percentage; namely, the better mineralization effect was possibly due to the better calcium chelation capacity of the polymer. Since the process of mineralization largely utilized the surrounding calcium, this result could be due to

**FIGURE 6.** Representative SEM images (A and B) and a comparison with Alizarin red mineralization staining (C). SEM images demonstrate the differences in the polymer-calcium complexes, indicative of the chelation capacities of the different polymer ratios, whereby the increasing amount of VPA (0, 34, and 100 mol % VPA) show increased levels of granulation/particle formation when exposed to the same concentrations of Ca2+ ions (A). The subsequent effects of the different AA:VPA ratio on the culture of SaOS-2 cells, is demonstrated with a lower magnification image is inset (B); the differences in particle formation of morphology of particles was considered to play a role in the mineralization behavior in association with cells. Dark areas are indicative of acellular regions on the surface of the thermanox coverslip and appear featureless in contrast with the bright areas of mineralized material. In comparison to the SEM the calcium deposition observed by SEM could be correlated to the mineralization observed by alizarin red staining for calcium (C), where increasing the mol % VPA resulted in more agglomerated clusters of mineralization, whereas P-34 demonstrated a much more homogenous layer of mineralization with the presence of nodulelike formations.
FIGURE 7. Osteogenic effect of PVPA-co-AA polymer in SaOS-2 cells and human BM-MSCs. Representative photos showing the patterns and quantified percentage of ALP, in-vitro mineralization, and collagen staining of (A) human BM-MSCs and (B) SaOS-2 cells subject to P-34 polymer treatments at different concentrations. The graph shows means ± SD of data. Asterisks indicate significant (*p < 0.05, **p < 0.01, ***p < 0.001) increase in the staining percentage vs. the control at the same time point.
the unique calcium chelation property of the PVPA-co-AA: At a high PVPA-co-AA concentration (50 μg/mL or higher), all free calcium in media was chelated by the PVPA-co-AA in a soluble complex, hence cells have very little calcium available to form a mineralization matrix. At a lower PVPA-co-AA concentration, total Ca$^{2+}$ exceeds the PVPA chelation capacity; hence it formed calcium-PVPA-co-AA precipitates on the cell surface, and this calcium rich precipitate helped

FIGURE 8. Osteogenic marker gene expression in SaOS-2 cells and human BM-MSCs. (A) shows the osteogenic marker gene expression in human BM-MSCs at day 21 and 28, subject to P-34 polymer treatments at different concentrations. (B) shows the osteogenic marker gene expression in SaOS-2 cells at day 1 and 7, subject to P-34 polymer treatments at different concentrations. The data were normalized to housekeeping gene GAPDH rRNA and represent mean ± SD. Asterisks indicate significant (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$) difference between the samples at the same time point.
the cell mineralization. This proposed mechanism could also explain the controversial effects of PVPA from other studies, as the different PVPA concentrations could lead to completely different effects in bone mineralization.

Different appearances of the polymer-calcium complex at different VPA:AA ratios were found in our research. The mechanism for the formations of different polymer-calcium complexes is not well understood, particularly in relation to polymer-mediated mineralization. It is known that the charge, ionic composition and molecular weight can affect the size and shape for the formation of calcium phosphate crystals. However, there are limited studies regarding the thermodynamics that underpin the process. It was observed that the composition of a copolymer from AA and VPA could be optimized to improve the chelation capacity of either AA or VPA individually. 34 mol % PVPA-co-AA demonstrated the greatest calcium chelation capacity and, consequently, was associated with the formation of dense calcium-rich, nodule-like agglomerates. It is not clear whether the polymer itself improved cell-mediated mineralization or whether the formation of Ca-polymer complexes improved the distribution and density of mineralized matrix formation. However, it was apparent that there appeared to be a link between the type and concentration of polymer used in association with cell culture media, to enhance the osteogenic response of both an osteoblast-like cell-line and hBM-MSCs. Previously, Chou et al. described that the bone sialoprotein (BSP) and osteocalcin (OCN) expression of MC3T3 cells (osteoblastic cell line) were affected by the size of apatite crystals. Importantly, greater expression of both BSP and OCN were shown on larger crystals. In our study, we demonstrate that both the polymer ratio and concentration affect the degree of mineralization and consequently, an optimal polymer-calcium complex could be achieved to promote osteogenic differentiation and mineralization.

It has been shown that the osteogenic effect of P-34 on hBM-MSCs and SaOS-2 cells were both concentration dependent, and at the optimized concentration (5 µg/mL and 10 µg/mL concentration) P-34 treatment not only significantly increased in vitro mineralization at day 7 and the collagen synthesis at day 14 in SaOS-2 cells, but also significantly increased alkaline phosphatase activity, in vitro mineralization, and collagen synthesis at the relevant time points in hMB-MSCs. Interestingly, our PCR results suggested that the osteogenic effects on SaOS-2 cells and hBM-MSCs were from different mechanisms.

The PCR result showed that no difference was found in osteogenic genes expression in SaOS-2 cells between the P-34 treatment and control groups; suggesting that the P-34 does not affect SaOS-2 (mature osteoblast cells) gene expression. In contrast, all osteogenic gene expression in the hBM-MSCs culture were increased with the P-34 treatment. This is an interesting finding; as the mineralization results suggested that although P-34 increased mineralization on both SaOS-2 cells and hBM-MSCs at the optimized concentration, the underlying mechanisms for both cells were probably different. The osteoconductivity of P-34, particularly the increased in-vitro mineralization in SaOS-2 cells with P-34 treatment, was probably due to the PVPA-co-AA chemical structure, which mimics the action of bisphosphonates, due to a similar chemical structure and the ability of the PO3H2 group to chelate Ca2+ ions, essentially forming a “bone hook,” with the potential to enhance bone mineralization. Furthermore, bisphosphonates exert stimulatory effects on MSCs proliferation and osteogenic differentiation. As PVPA-co-AA has the chemical structure which resembles bisphosphonates, the polymer may mimic the action of bisphosphonate on hBM-MSCs through as yet an unknown mechanism. More importantly, here we have shown for the first time an osteoinductive effect of PVPA-co-AA on hBM-MSCs. Interestingly this effect was not only achieved by calcium chelation of the PVPA-co-AA chemical structure, but P-34 also enhanced osteogenic differentiation of hBM-MSCs at molecular level influencing osteogenic gene expression.

CONCLUSION
This is the first study to report the direct osteogenic effect of PVPA-co-AA polymer on MSCs and osteoblasts. With the different VPA:AA ratios in the PVPA-co-AA polymer, different osteogenic effects were observed. Among the formulations investigated, the copolymer with 34% VPA (%mol) demonstrated the best osteogenic effects, which not only enhanced osteoconductivity in SaOS-2 cells (mature osteoblast-like cells), but also promoted osteoinductivity in hBM-MSCs. We also found a strong correlation between the osteogenic effects and the calcium chelation capacity of the investigated copolymers. More importantly, this is the first study to report that different concentrations of PVPA-co-AA could also lead to differential effects on bone mineralization, together with a possible mechanism. This proposed mechanism can also explain the conflicting effects of PVPA from other studies. Moreover, with the optimized P-34 concentration defined in this study, further work is underway to investigate the performance of P-34 incorporated tissue engineering scaffold in vitro and in vivo. The knowledge will be critical when incorporating PVPA-co-AA polymers in the design of novel bioactive polymeric tissue engineering scaffolds for future clinical applications.

ACKNOWLEDGMENT
This research was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) grant BB/K020331/1. R.E.D. is funded by a BBSRC doctoral training partnership (DTP) studentship. We thank David Farrar, Alan Horner and Paul Souter of Smith & Nephew for support and encouragement.

NOTE
The authors declare no competing financial interest.

REFERENCES
1. Calori GM, Mazza E, Colombo M, Ripamonti C. The use of bone-graft substitutes in large bone defects: Any specific needs? Injury 2011;42 Suppl 2:S56–S63.
2. Bai X, Lu SY, Cao Z, Gao C, Duan H, Xu X, Sun L, Gao N, Feng C, Liu M. Self-reinforcing injectable hydrogel with both high water content and mechanical strength for bone repair. Chem Eng J 2016;288:546–556.
3. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005;23:47–55.
4. Li X, Ding J, Wang J, Zhuang X, Chen X. Biomimetic biphasic scaffolds for osteochondral defect repair. Regen Biomater 2015;2:221–228.
5. Cao H, Kuboyama N. A biodegradable porous composite scaffold of PGA/beta-TCP for bone tissue engineering. Bone 2010;46:386–395.
6. Phipps MC, Clem WC, Grunda JM, Clines GA, Bellis SL. Increasing the pore sizes of bone-mimetic electrospun scaffolds comprised of polycaprolactone, collagen I and hydroxyapatite to enhance cell infiltration. Biomaterials 2012;33:524–534.
7. Xue W, Bandyopadhyay A, Bose S. Polycaprolactone coated porous tricalcium phosphate scaffolds for controlled release of protein for tissue engineering. J Biomed Mater Res B, Appl Biomater 2009;91:831–838.
8. Guo B, Lei B, Li P, Ma PX. Functionalized scaffolds to enhance tissue regeneration. Regen Biomater 2015;2:47–57.
9. Bat E, van Kooten TG, Harmsen MC, Plantinga JA, van Luyn MJ, Feijen J, Grijs HW. Physical properties and erosion behavior of polylactide-co-epsilon-caprolactone) networks. Macromol Biosci 2013;13:573–583.
10. Kim YK, Gu LS, Bryan TE, Kim JR, Chen L, Liu Y, Yoon JC, Breshchi L, Pashley DH, Tay FR. Mineralisation of reconstituted collagen using polyvinylphosphonic acid/polyacrylic acid templating matrix protein analogues in the presence of calcium, phosphate and hydroxyl ions. Biomaterials 2010;31:6618–6627.
11. Bassi AK, Gough JE, Zakikhani M, Downes S. The chemical and physical properties of poly(epsilon-caprolactone) scaffolds functionalised with poly(phenyl phosphonic acid-co-acrylic acid). J Tissue Eng 2011;2011:615328.
12. Bassi A, Gough J, Downes S. A novel phosphate for the repair of critical bone defects. J Tissue Eng Regen Med 2012;6:833–840.
13. Bose S, Roy M, Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trend Biotechnol 2012;30:546–554.
14. Thula TT, Svedlund F, Rodriguez DE, Podschun J, Pendi L, Gower LB. Mimicking the nanostructure of bone: Comparison of polymeric process-directing agents. Polymers 2011;3:10–35.
15. Abuvea CD, Lee BT. Poly(vinylphosphonic acid) immobilized on chitosan: A glycosaminoglycan-inspired matrix for bone regeneration. Int J Biol Macromol 2014;64:294–301.
16. Lin YJ, Hsu FC, Chou CW, Wu TH, Lin HR. Poly(acrylic acid)-chitosan-silica hydrogels carrying platelet gels for bone defect repair. J Mater Chem B 2014;2:8329–8337.
17. Larsson M, Bergstrand A, Beslag M, van Vooren C, Larsson A. Nanocomposites of polyacrylic acid nanogels and biodegradable polyhydroxybutyrates for bone regeneration and drug delivery. J Nanomater 2014.
18. Dey RE, Zhong X, Youle PJ, Wang QG, Wimpenny I, Downes S, Hoyland JA, Watts DC, Gough JE, Budd PM. Synthesis and characterization of poly(vinylphosphonic acid-co-acrylic acid) copolymers for application in bone tissue scaffolds. Macromolecules 2016;49:7.
19. Hernigou P, Poignard A, Beaujean F, Roudard H. Percutaneous autologous bone-marrow grafting for nonunions - Influence of the number and concentration of progenitor cells. J Bone Joint Surg-Am Vol 2005;87A:1430–1437.
20. Wang QG, El Haj AJ, Kuiper NJ. Glycosaminoglycans in the peri- cellular matrix of chondrons and chondrocytes. J Anat 2008;213:266–273.
21. Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod 2002;17:1304–1309.
22. Giuliani AL, Adinolfi E, Roncato C, Colognesi D, Amoroso F, Zordan T, Wang QG, Capece M, De Marchi E, Gartland A, Di Virgilio F. Role of P2X7 receptor splice variants in osteosarcoma. Pinihef Signal 2014;10:832–833.
23. Chen C, Yang S, Zhang M, Zhang Z, Zhang B, Han D, Ma J, Wang X, Hong J, Guo Y, Okunieff P, Zhang L. In vitro Sirius Red collagen assay measures the pattern shift from soluble to deposited collagen. Adv Exp Med Biol 2013;765:47–53.
24. Minogue BM, Richardson SM, Zeef LA, Freemont AJ, Hoyal JA. Characterization of the human nucleus pulposus cell phenotype and evaluation of novel marker gene expression to define adult stem cell differentiation. Arthritis Rheum 2010;62:3695–3705.
25. Delacruz MO, Belloni L, Delsanti M, Dalbiez JP, Spalla O, Driford M. Precipitation of highly-charged polyelectrolyte solutions in the presence of multivalent salts. J Chem Phys 1995;103:5781–5791.
26. Arakawa T, Timasheff SN. Mechanism of protein salting in and salting out by divalent-cation salts - balance between hydration and salt binding. Biochemistry 1984;23:5912–5923.
27. Koutsopoulos S. Synthesis and characterization of hydroxyapatite crystals: A review study on the analytical methods. J Biomed Mater Res 2002;62:600–612.
28. Palazzo B, Walsh D, Iafisco M, Foresti E, Bertinetti L, Mantra G, Bianchi CL, Cappelletti G, Roveri N. Amino acid synergetic effect on structure, morphology and surface properties of biomimetic apatite nanocrystals. Acta Biomater 2009;5:1241–1252.
29. Bee K, Taubert A. New developments in polymer-controlled, bioinspired calcium phosphate mineralization from aqueous solution. Acta Biomater 2013;9:6263–6321.
30. Jones JR, Tsigkou O, Coates EE, Stevens MM, Polak JM, Hench LL. Extracellular matrix formation and mineralization on a phosphate-free porous bioactive glass scaffold using primary human osteoblast (HOB) cells. Biomaterials 2007;28:1653–1663.
31. Barrere F, von Blitterswiik CJ, de Groot K. Bone regeneration: Molecular and cellular interactions with calcium phosphate ceramics. Int J Nanomed 2006;1:317–332.
32. Chou YF, Huang W, Dunn JC, Miller TA, Wu BM. The effect of biomimetic apatite structure on osteoblast viability, proliferation, and gene expression. Biomaterials 2005;26:285–295.
33. Boskey A, Paschalis E. Matrix proteins and biomineralization. In: Davies J, editor. Bone Engineering. Toronto: Em Square; 2001. p 44–61.
34. Aqhtani NR, Logan NJ, Meghji S, Leeson R, Brett PM. Low dose effect of bisphosphonates on hMSCs osteogenic response to titanium surface in vitro. Bone Rep 2017;6:64–69.